This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

The Deal: Pfizer's 3-Way Split Preps Company Long Term

NEW YORK ( The Deal) -- As expected, Pfizer (PFE - Get Report) announced last week its plans to split its generics business into a distinct unit. What analysts and investors didn't expect was that Pfizer would divide itself into three parts instead of just two.

Pfizer will formally separate into three distinct businesses and integrate emerging markets into each, with the separation of financials expected to begin starting with Pfizer's fiscal 2014, Chairman and CEO Ian Read said during the company's sales and earnings conference call with investors Tuesday, July 30.

Pfizer's generics business, now called the "value products group," includes brands that have lost their exclusivity and mature products expected to go generic by 2015. This sector also retains Pfizer's biosimilars portfolio.

Many investors believe the move is in preparation for a spinoff into a separate generics company or for an outright sale, but Pfizer isn't ready to say that.

The two other segments include the expected unit of drugs with exclusivity beyond 2015, called "innovative products" and led by Geno Germano. That unit, which was the one industry watches hadn't expected in the reognization, combines vaccines, oncology and consumer healthcare products, and will be headed up by Amy Schulman.

The rationale for the third unit, Read said, is that Germano's group is operationally and commercially quite different from the vaccines group. The products in Germano's group target a collection of large disease areas that are detailed to both primary care and specialist physicians. Contrast that to the vaccines business, which is smaller, with a distinct culture, dedicated research facilities and a research focus.

"I thought it was very important for those businesses to maintain their unique focus and extend it globally," Read said. Plus, he "didn't want vaccines to be subsumed into a larger primary care business."

"Each has a different operating model with distinct specializations around science, talent and market approach," Read noted.

The generics segment will maintain collaborations for broadening Pfizer's off-patent business, including its partnerships with Mylan Pharmaceuticals in Japan, China's Zhejiang Hisun Pharmaceutical and Laboratorio Teuto Brasileiro in Brazil.

Like several other lumbering pharma giants, Pfizer needed to do something to get lean and mean. It reported revenue of roughly $13 billion for the second quarter, down 7% from 2012's second quarter revenue of $14 billion. The downturn reflects loss of exclusivity for Lipitor and continued volatility in emerging markets.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
PFE $34.32 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%
GOOG $558.40 0.00%
TSLA $203.34 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs